Osi Pharmaceuticals Inc. (OSIP) rated Buy with price target $45 by Lazard Capital
Lazard Capital rated Buy Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on 12/05/2008. Previously Lazard Capital rated Buy Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on
10/26/2007., when the stock price was $39.34. Since then, Osi Pharmaceuticals Inc. has lost 21.05% as of 06/08/2010's recent price of $31.06. If you would have followed the previous Lazard Capital's recommendation on OSIP, you would have lost 21.04% of your investment in 956 days.
OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.
Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders.
Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.